Hormone Therapy and Cardiovascular Health: Balancing Risks and Outcomes

Navigating gender-affirming care often requires a deep understanding of the physiological changes that accompany medical transition. Hormone Replacement Therapy (HRT) is a cornerstone of gender affirmation for many transgender, non-binary, and intersex individuals. While HRT offers profound psychological and physical alignment, its effects on cardiovascular health remain a subject of ongoing clinical study and active discussion within the medical community.

For patients and clinicians alike, evaluating cardiovascular risk is not about choosing between heart health and identity affirmation. Gender-affirming care is medically necessary healthcare that significantly improves mental health and quality of life. Understanding how estrogen, anti-androgens, and testosterone interact with the cardiovascular system empowers individuals to make informed decisions and maintain lifelong health.

The Physiology of Feminising Hormone Therapy

Feminising HRT typically involves a combination of estrogen, such as estradiol, and an anti-androgen like spironolactone, cyproterone acetate, or a GnRH agonist. Estrogen influences the body in several ways, including fat redistribution, skin softening, and breast tissue development, but it also interacts with the vascular system and liver metabolism.

Exogenous estrogen can alter blood lipid profiles and coagulation pathways. When taken orally, estrogen undergoes first-pass metabolism in the liver. This process can increase the production of specific clotting factors, slightly raising the risk of venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism.

The route of administration plays a critical role in managing this risk. Transdermal estrogen, delivered via patches or gels, bypasses liver metabolism entirely. Clinical guidelines from major endocrine societies highlight that transdermal routes present a significantly lower risk of blood clots compared to oral formulations, making them a preferred choice for individuals with pre-existing cardiovascular risk factors or those over the age of 40.

The Physiology of Masculinising Hormone Therapy

Masculinising HRT primarily uses testosterone, administered through intramuscular injections, subcutaneous injections, or transdermal gels. Testosterone promotes the development of secondary male sex characteristics, such as facial hair, voice deepening, and muscle mass increase.

In terms of cardiovascular markers, testosterone therapy typically leads to changes in blood lipid levels. It is common to see a slight decrease in high-density lipoprotein (HDL), often referred to as good cholesterol, and a mild increase in low-density lipoprotein (LDL) and triglycerides. Additionally, testosterone stimulates the production of red blood cells.

"Managing cardiovascular health during hormone therapy relies on personalised care, regular monitoring, and choosing the right route of administration for each individual."

In some individuals, this increase in red blood cells can lead to erythrocytosis, a condition where the blood becomes thicker, potentially increasing the workload on the heart and raising blood pressure. Regular blood monitoring allows healthcare providers to track hematocrit levels and adjust dosages before complications arise.

Examining Clinical Evidence and Long-Term Outcomes

Large observational studies have provided valuable insights into the long-term health outcomes of transgender individuals on HRT. Research indicates that while there are measurable changes in risk markers, the overall cardiovascular risk profile remains manageable through standard medical care.

For transgender women, the elevated risk of venous thromboembolism is most pronounced during the first few years of treatment and with older, synthetic estrogens such as ethinyl estradiol. Modern treatment protocols almost exclusively use bioidentical estradiol, which carries a much lower side-effect profile.

For transgender men, long-term studies show that while testosterone changes cholesterol numbers, it does not lead to a drastic rise in major cardiovascular events like heart attacks or strokes when compared to cisgender men. Instead, the risk profile tends to align more closely with that of the broader male population over time.

Risk Assessment and Baseline Health Screening

Before starting hormone therapy, comprehensive baseline screening provides a clearer picture of an individual's overall health. Doctors typically evaluate several key factors during this initial assessment:

• Blood pressure measurements to establish a clear baseline.
• Lipid panels to measure baseline cholesterol and triglyceride levels.
• Glycated hemoglobin (HbA1c) tests to check for pre-diabetes or diabetes.
• Full blood count to evaluate initial red blood cell concentrations.
• Personal and family medical history regarding blood clots, heart attacks, and strokes.

Identifying pre-existing conditions does not mean hormone therapy is ruled out. Instead, it allows clinicians to tailor the regimen, select the safest administration method, and treat co-occurring conditions effectively alongside gender affirmation.

Lifestyle Factors and Preventive Strategies

Hormone therapy is only one component of cardiovascular health. Modifiable lifestyle factors play a major role in mitigating potential risks associated with HRT.

• Tobacco cessation: Smoking significantly increases the risk of blood clots and cardiovascular disease, especially when combined with estrogen therapy.
• Regular physical activity: Aerobic exercise helps maintain healthy blood pressure, lowers LDL cholesterol, and supports overall cardiovascular function.
• Balanced nutrition: Diets rich in whole grains, vegetables, lean proteins, and healthy fats support optimal lipid levels.
• Stress management: Chronic stress affects blood pressure and heart health, making mental health support an integral part of physical wellness.

Addressing these factors offers individuals a practical way to protect their cardiovascular system while continuing their gender-affirming medical treatments safely.

Monitoring Protocols and Ongoing Care

Ongoing monitoring is essential for anyone on long-term hormone therapy. Routine follow-ups ensure that hormone levels stay within target physiological ranges and that potential complications are caught early.

During the first year of therapy, appointments usually occur every three to six months. Once hormone levels stabilise and clinical goals are met, annual or bi-annual check-ups are standard practice.

Regular appointments typically include monitoring hormone levels (estradiol or testosterone), checking blood pressure, and performing periodic lipid panels and full blood counts. Adjusting dosages based on these results ensures the therapy remains both effective for gender affirmation and safe for the vascular system.

Cardiovascular Health and Intersex Lived Experience

Intersex individuals, who are born with sex characteristics that do not fit typical binary definitions, also navigate complex hormonal landscapes. Some intersex people require hormone therapy due to congenital conditions, surgical history, or personal gender alignment.

Cardiovascular consideration for intersex individuals requires a highly individualized approach. Hormonal variations present from birth or resulting from medical interventions earlier in life mean that standard binary reference ranges may not always apply directly. Healthcare providers must work closely with intersex patients to establish personalized baseline health metrics and monitor cardiovascular markers with care.

Accessible Healthcare and Community Support

Access to informed, respectful healthcare is vital for managing long-term outcomes in gender-affirming care. When clinicians understand the nuances of hormone therapy, patients can receive high-quality preventive care without facing discrimination or denial of service.

Cardiovascular wellness and gender affirmation go hand in hand. With proper monitoring, tailored administration methods, and healthy lifestyle habits, individuals on hormone therapy can live fulfilling, healthy lives with strong heart health.

If you found this explainer helpful, consider supporting the site. This platform is run by Jordyn Kao, an intersex and transgender woman in South Africa currently raising funds for medically necessary, gender-affirming surgery. Your support helps cover essential medical costs and keeps free, accessible educational content available for everyone.